Skip to main content
Premium Trial:

Request an Annual Quote

Vela Diagnostics NGS HCV Assay Receives CE Mark

NEW YORK (GenomeWeb) – Vela Diagnostics announced today that it its next-generation sequencing-based hepatitis C genotyping assay has received CE marking, clearing the test for in vitro diagnostic use in Europe. 

The Sentosa SQ HCV genotyping assay covers clinically relevant regions of NS3, NS5A, and NS5B and detects genotypes 1 through 6, as well as subtypes 1a and 1b, according to the company. It runs on the company's highly automated Sentosa NGS platform. 

The HCV assay was approved for diagnostic use in Australia last month.

Last year the firm launched its CE-marked Sentosa SQ Thyroid Cancer Panel, a next-gen sequencing-based assay that simultaneously detects 105 hot spots in 10 genes associated with thyroid cancer. 

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.